Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Myriad Genetics (MYGN) Gross Margin (2016 - 2025)

Historic Gross Margin for Myriad Genetics (MYGN) over the last 17 years, with Q3 2025 value amounting to 69.91%.

  • Myriad Genetics' Gross Margin fell 3200.0% to 69.91% in Q3 2025 from the same period last year, while for Sep 2025 it was 70.36%, marking a year-over-year increase of 76500.0%. This contributed to the annual value of 69.89% for FY2024, which is 12500.0% up from last year.
  • As of Q3 2025, Myriad Genetics' Gross Margin stood at 69.91%, which was down 3200.0% from 71.23% recorded in Q2 2025.
  • Myriad Genetics' Gross Margin's 5-year high stood at 74.66% during Q2 2021, with a 5-year trough of 33.24% in Q4 2022.
  • Over the past 5 years, Myriad Genetics' median Gross Margin value was 69.98% (recorded in 2023), while the average stood at 67.0%.
  • Its Gross Margin has fluctuated over the past 5 years, first plummeted by -382800bps in 2022, then surged by 299400bps in 2024.
  • Myriad Genetics' Gross Margin (Quarter) stood at 71.52% in 2021, then crashed by -54bps to 33.24% in 2022, then grew by 25bps to 41.71% in 2023, then soared by 72bps to 71.65% in 2024, then decreased by -2bps to 69.91% in 2025.
  • Its last three reported values are 69.91% in Q3 2025, 71.23% for Q2 2025, and 68.5% during Q1 2025.